Who is Didier Raoult and Why is He Controversial?

Didier Raoult is a French microbiologist who, before 2020, was best known for discovering giant viruses and building one of the largest infectious disease research centers in Europe. His controversy stems almost entirely from his promotion of hydroxychloroquine as a COVID-19 treatment during the early months of the pandemic, a claim that was later contradicted by large-scale clinical trials and linked to serious patient harm. But the fallout didn’t stop at one drug recommendation gone wrong; investigations into his institute have since uncovered widespread research ethics violations stretching back years before the pandemic began.

A Towering Career in Microbiology

Before COVID-19 turned him into a household name in France, Raoult had a genuinely distinguished scientific career. He was among the researchers who, in 2003, identified and characterized Mimivirus, a particle so large it had originally been mistaken for a bacterium. The discovery changed the field of virology by demonstrating that viruses could be far bigger and more genetically complex than anyone had assumed.

The Mimivirus genome, sequenced and published in 2004, turned out to contain over 1.18 million base pairs and roughly 1,262 genes, a scale previously unthinkable for a virus. About a tenth of those genes resembled proteins with known functions, meaning the vast majority were entirely novel.

Raoult went on to co-discover several other giant virus families and became one of the most cited microbiologists in the world. He led the Institut Hospitalo-Universitaire Méditerranée Infection (IHU-MI) in Marseille, a large research hospital devoted to infectious disease. The institute was lavishly funded by the French government and became a powerful research hub. By the time SARS-CoV-2 arrived, Raoult was an established scientific authority with an enormous institutional platform and a combative public persona. He was already known in France for challenging mainstream scientific consensus and cultivating a following through YouTube videos about infectious diseases.

The Hydroxychloroquine Claim That Started It All

In March 2020, with COVID-19 spreading rapidly and no proven treatments available, Raoult’s team published the study that would make him globally famous. It was a small, open-label, non-randomized trial: patients at his Marseille hospital were given 600 mg of hydroxychloroquine daily, some with the antibiotic azithromycin added, and their viral loads were tracked using nasopharyngeal swabs. Patients from another center who were not treated, or who refused the drug, served as controls.

The study reported that the treated patients cleared the virus faster. It was a dramatic claim at a terrifying moment, and the paper went viral. Within days it had been shared millions of times on social media. Then-U.S. President Donald Trump publicly endorsed hydroxychloroquine, and health agencies in several countries began stockpiling the drug. Raoult followed up quickly with a second study, this time treating 80 patients with the same combination. That study was also uncontrolled and non-comparative, meaning there was no randomized group receiving a placebo or standard care for proper comparison.

⁴

Methodological problems were apparent almost immediately. The initial study had only 36 patients, six of whom were dropped from the analysis after enrollment because they worsened or died before being retested. The controls were not from the same hospital, were not matched to the treated patients by disease severity, and were not randomized. Scientists around the world pointed out that these design flaws made it impossible to draw reliable conclusions about whether the drug was helping. Raoult dismissed these criticisms publicly, framing his detractors as out-of-touch academics disconnected from patient care.

What the Large Trials Actually Found

The question of whether hydroxychloroquine worked against COVID-19 was eventually answered by some of the largest clinical trials ever conducted. The United Kingdom’s RECOVERY trial, a massive pragmatic study involving thousands of hospitalized patients, enrolled participants into a hydroxychloroquine arm and tracked 28-day mortality. The results were unambiguous: about 27% of patients receiving hydroxychloroquine died within 28 days, compared with 25% in the usual-care group. Hydroxychloroquine patients were also less likely to be discharged alive and more likely to need mechanical ventilation.

⁵

The RECOVERY trial was so clearly negative that enrollment in the hydroxychloroquine arm was stopped early for futility. A similar pattern emerged in the WHO’s SOLIDARITY trial and in dozens of smaller randomized trials around the world. When these trials were combined in a meta-analysis covering 28 randomized controlled trials and over 10,000 patients, the pooled result was that hydroxychloroquine treatment was associated with an 11% increase in the odds of dying.

⁶

The evidence was consistent across subgroups and across trial designs. No subset of patients appeared to benefit. The meta-analysis authors stated plainly that hydroxychloroquine was associated with increased mortality in COVID-19 patients, and that chloroquine showed no benefit either.

⁶

A Drug That Made Things Worse

Part of the reason hydroxychloroquine may have increased mortality is cardiac toxicity. Both hydroxychloroquine and azithromycin are known to prolong the QT interval, a measure of electrical activity in the heart. When the QT interval stretches too far, the heart becomes vulnerable to dangerous rhythm disturbances, including a potentially fatal arrhythmia called torsades de pointes.

A study of 90 hospitalized COVID-19 patients given hydroxychloroquine found that about one in five developed dangerously prolonged QT intervals. When azithromycin was added, the problem got worse: the median change in QT interval was significantly larger in patients receiving the combination than in those on hydroxychloroquine alone. Ten patients had to have the drug stopped early because of adverse events, including one case of torsades de pointes.

⁷

A separate study confirmed that the hydroxychloroquine-azithromycin combination significantly prolonged the QT interval in COVID-19 patients and could cause life-threatening arrhythmia. The authors warned that this risk demanded careful consideration given the drug’s unproven efficacy.

⁸

This is an important part of the story because Raoult’s protocol specifically combined hydroxychloroquine with azithromycin. The combination he promoted was the very pairing that carried the greatest cardiac risk.

Estimating the Human Cost

A 2023 modeling study attempted to estimate how many hospital deaths globally could be attributed to the widespread compassionate use of hydroxychloroquine during the first wave of COVID-19. Using data on HCQ prescribing rates across multiple countries and the excess mortality signal from the clinical trials, the researchers estimated that roughly 16,990 in-hospital deaths were associated with hydroxychloroquine use, with a range of about 6,300 to 19,300. The authors acknowledged the imprecision of these estimates but argued the findings illustrated the danger of repurposing drugs based on low-quality evidence.

⁹

That number is sobering. Even the lower bound suggests thousands of people died who might have survived with standard care alone. The modeling is necessarily rough, because tracking which patients received the drug and what would have happened without it is difficult after the fact. But the direction is clear: a treatment promoted as life-saving during a pandemic probably cost lives instead.

Research Ethics Violations at the Institute

The hydroxychloroquine controversy brought scrutiny not just to the drug itself but to the way Raoult’s institute conducted research. What investigators found went far beyond the pandemic studies. An analysis of published papers from the IHU-MI identified ethical or legal concerns in 248 studies that had all been conducted under the same ethics approval number, despite involving different subjects, different biological samples, and different countries. Another 39 studies on human subjects contained no ethics approval reference at all.

¹⁰

A follow-up investigation expanded the scope dramatically. Researchers identified ethical or legal concerns in 853 articles from the institute. These included at least 75 papers with ethics approvals obtained only after the research was already done, 194 papers describing work conducted abroad without mentioning any local ethics approvals, and 343 papers that did not mention ethics approval at all. Among 374 articles for which the investigators actually obtained the cited ethics approval documents, at least 304 described sample collections that were not covered by the approval they referenced. That means over 80% of the papers they could verify in detail had mismatched or inadequate ethics clearance.

¹¹

The scale of these findings is extraordinary. Research ethics approvals exist to protect human subjects, ensuring that people whose blood, tissue, or clinical data are used in studies have consented and that an independent board has judged the research acceptable. When hundreds of published papers lack valid approvals, it raises questions about whether the patients involved were properly informed and whether the research was adequately overseen.

Criminal Charges and Regulatory Action

The institutional problems eventually attracted the attention of France’s medicines agency, the ANSM. After conducting inspections of the IHU, the agency announced that it had uncovered “serious breaches” in the institute’s biomedical research, and that some of these breaches predated the COVID-19 pandemic entirely. The ANSM stated it would file criminal charges with the Marseille public prosecutor, noting that two of the breaches might qualify as criminal offenses.

¹²

Raoult retired from his position as head of the IHU in 2022, though he continued to make public statements defending his record. The French medical establishment’s response was mixed: some institutions moved to distance themselves from him, while he retained vocal supporters who saw the investigations as politically motivated retaliation against a maverick scientist. The legal proceedings remain a significant test of whether France’s regulatory framework can hold a powerful institutional figure accountable for research conduct.

How Raoult Became a Folk Hero

One of the more remarkable aspects of the Raoult controversy is that the negative evidence against hydroxychloroquine did not diminish his popularity. If anything, it enhanced it. In France, Raoult cultivated a persona as a plain-speaking provincial doctor standing up against Parisian elites and cautious bureaucrats. His YouTube channel drew millions of views. He leaned into an anti-establishment identity, framing the pandemic response as a battle between frontline clinicians willing to act and timid academics paralyzed by procedure.

This resonated widely, and not just in France. Around the world, hydroxychloroquine became a political symbol. People who distrusted government pandemic responses or who felt mainstream medicine was ignoring simple, cheap treatments latched onto Raoult’s message. The dynamic was self-reinforcing: the more the scientific establishment criticized his methods, the more his supporters saw him as persecuted for telling the truth. This pattern was not unique to Raoult, but the scale of his scientific credentials made it unusually potent. He was not a fringe blogger; he was one of the most published microbiologists alive.

The gap between Raoult’s genuine scientific accomplishments and the quality of his hydroxychloroquine evidence is the core tension of his story. A researcher who helped rewrite textbook virology produced COVID-19 treatment studies that would have been considered methodologically inadequate for an undergraduate thesis. Small, uncontrolled, non-randomized trials with dropped patients are the kind of evidence that experienced scientists know better than to over-interpret. The most charitable reading is that the early pandemic was a chaotic moment and Raoult genuinely believed he was helping patients. The less charitable reading is that he leveraged a crisis to promote himself and his institute, dismissing contrary evidence along the way.

What the Raoult Case Reveals About Science Under Pressure

The Raoult affair exposed vulnerabilities in how science communicates during emergencies. Preprint servers and social media allowed preliminary findings to reach millions of people before peer review could evaluate them. Governments, desperate for solutions, incorporated those findings into policy. By the time high-quality trials delivered clear answers, the drug had already been given to hundreds of thousands of patients worldwide.

It also highlighted the limitations of the “trust the expert” heuristic. Raoult’s credentials were real. His citation count was enormous. His institution was government-funded and prestigious. For a non-specialist trying to evaluate competing claims in early 2020, there was no obvious reason to dismiss his recommendations. The tools that a scientist would use to evaluate his evidence, scrutinizing study design, control groups, and statistical methods, are not tools most people have. This meant that the scientific community’s criticisms, which were valid and were raised almost immediately, sounded to many people like jealous rivals attacking a successful outsider.

The ethics violations uncovered at the IHU also raise uncomfortable questions for the broader system. Hundreds of papers with questionable or missing ethics approvals were published in peer-reviewed journals over many years. Journals, reviewers, and institutional oversight bodies all had opportunities to catch these problems and did not. The post-pandemic investigations were driven largely by independent researchers and science integrity sleuths, not by the institutions that were supposed to be providing oversight in the first place. Whether the scientific publishing ecosystem can fix these structural gaps remains an open question, and one that extends well beyond any single researcher or institute.